SAN DIEGO, Oct. 21, 2020
/PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:
VKTX), a clinical-stage biopharmaceutical company focused on the
development of novel therapies for metabolic and endocrine
disorders, announced today that the company will release financial
results for the third quarter 2020, after the market close on
Wednesday, October 28, 2020.
The company will host a conference call to discuss financial
results and general corporate updates beginning at 4:30 p.m. Eastern Time on Wednesday, October 28,
2020. To participate on the conference call, please dial
(844) 850-0543 from the U.S. or (412) 317-5199 from outside the
U.S. In addition, following the completion of the call, a
telephone replay will be accessible until November 4, 2020 by dialing (877) 344-7529 from
the U.S. or (412) 317-0088 from outside the U.S. and entering
conference ID #10148182. Those interested in listening to the
conference call live via the internet may do so by visiting the
Webcasts page of Viking's website at
http://ir.vikingtherapeutics.com/webcasts. An archive of the
webcast will also be available on the Webcasts page of the
company's website for 30 days.
About Viking Therapeutics, Inc.
Viking Therapeutics is a clinical-stage biopharmaceutical
company focused on the development of novel, orally available,
first-in-class or best-in-class therapies for the treatment of
metabolic and endocrine disorders. Viking's research and
development activities leverage its expertise in metabolism to
develop innovative therapeutics designed to improve patients'
lives. The company's clinical programs include VK2809, a
novel, orally available, small molecule selective thyroid hormone
receptor beta agonist for the treatment of lipid and metabolic
disorders, which is currently being evaluated in a
Phase 2b study for the treatment of biopsy-confirmed
non-alcoholic steatohepatitis (NASH) and fibrosis. In a Phase
2 trial for the treatment of non-alcoholic fatty liver disease
(NAFLD) and elevated LDL-C, patients who received VK2809
demonstrated statistically significant reductions in LDL-C and
liver fat content compared with patients who received
placebo. The company is also developing VK0214, a novel,
orally available, small molecule selective thyroid hormone receptor
beta agonist for the treatment of X-linked adrenoleukodystrophy
(X-ALD). The company holds exclusive worldwide rights to a
portfolio of five therapeutic programs, including those noted
above, which are based on small molecules licensed from Ligand
Pharmaceuticals Incorporated.
For more information about Viking Therapeutics, please visit
www.vikingtherapeutics.com. Follow Viking on Twitter
@Viking_VKTX.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/viking-therapeutics-to-report-financial-results-for-third-quarter-2020-on-october-28-2020-301157221.html
SOURCE Viking Therapeutics, Inc.